Support Quality by Design using FT-NIR solutions

Support Quality by Design using FT-NIR solutions

Significance of the topic

Implementing Quality by Design (QbD) in pharmaceutical manufacturing requires inline, at-line or rapid off-line analytical measurements that inform control strategies rather than retrospective release testing. Fourier-transform near-infrared (FT-NIR) spectroscopy is a key Process Analytical Technology (PAT) tool that delivers fast, non-destructive chemical and physical information across many process stages. Embedding robust FT-NIR measurements into development and production workflows reduces product variability, accelerates process transfer, and supports continuous manufacturing and regulatory expectations for engineered quality.

Objectives and article overview

This document describes FT-NIR solutions intended to support QbD and PAT implementation in pharmaceutical workflows. It outlines instrument families suited for lab, at-line and in-line monitoring, highlights software and sampling options that enable scalable deployment, and situates FT-NIR within a broader analytical ecosystem for discovery, problem solving and quality assurance. The overview emphasizes practical features needed for reliable production use: wavelength precision, ruggedness, calibration transfer, real-time feedback and compliance with hazardous-area requirements.

Methodology

FT-NIR spectroscopy measures overtone and combination bands primarily related to C-H, O-H and N-H vibrations, providing rapid compositional and physical state information. For process use, FT-NIR is applied in several sampling modes:

• Transmission – useful for thin films, clear melts or tablets where light passes through the sample.
• Diffuse reflectance (integrating sphere) – suited for powders and solid formulations to capture representative bulk signals.
• Fiber-optic probe measurements – enable in-line or on-line monitoring by routing light to and from a process stream.

Chemometric models (multivariate calibration) are built from representative sample sets to relate spectral variance to properties such as assay, moisture, blend uniformity, particle size or API polymorphism. For process control, model transferability, maintenance and validation are critical; the combination of instrument stability and robust software workflows reduces calibration drift and simplifies transfer between instruments and sites.

Instrumentation used

The described solutions include matched laboratory and process FT-NIR platforms and complementary analytical instrumentation used in development and QC contexts:

• Antaris II FT-NIR – compact benchtop for off-line or at-line measurements at point-of-use with high wavelength precision and rugged construction designed for reproducible lab-to-process performance.
• Antaris MX FT-NIR – designed for in-line and on-line process monitoring with fiber-optic multiplexing, real-time communication capabilities and an ATEX-rated variant for operation in hazardous areas.
• Antaris II MDS Method Development Sampling System – turnkey sampling that integrates transmission, fiber-optic and integrating-sphere diffuse reflectance methods to support model creation across sampling modes.
• Result Software Suite – unified software environment for development, routine use and process deployment that supports technicians through to experienced chemists and facilitates calibration transfer.
• Complementary instruments mentioned for broader pharmaceutical workflows: DXR2xi Raman Imaging Microscope, Nicolet iS50 and iS5 FTIR spectrometers, HAAKE MARS rheometer, Pharma 11 twin-screw extruder, HAAKE Viscotester IQ. These support formulation development, imaging, rheological characterization and continuous manufacturing trials.

Main findings and discussion

Although this material is a product-focused overview rather than a primary research report, the key practical conclusions are:

• FT-NIR, when implemented with stable hardware and consistent sampling, supports reproducible measurements suitable for QbD and PAT workflows.
• Instrument design and wavelength precision are central to enabling calibration transfer; rigorous factory testing and ruggedization reduce inter-instrument variability.
• Integrating a single software suite across lab and process environments simplifies training and standardizes model deployment and maintenance.
• Fiber-optic multiplexing and real-time data communication enable scalable in-line monitoring, providing actionable process feedback to support timely control interventions.
• Safety considerations such as ATEX certification expand applicability into hazardous production areas, increasing the scope for real-time PAT in pharmaceutical plants.

Key practical considerations for users include ensuring representative sampling, appropriate chemometric model validation, periodic model maintenance (e.g., updating models with new process variability), and alignment of software and hardware configurations to allow seamless calibration transfers between lab and process instruments.

Benefits and practical applications

FT-NIR solutions support several high-value pharmaceutical applications:

• Raw material identification and incoming QC to prevent use of incorrect or contaminated inputs.
• Blend uniformity and end-point detection for granulation and mixing operations.
• Moisture determination during drying and granulation to guide process end-points.
• Assay and content uniformity estimation for tablets and solid dose forms, enabling at-line release strategies.
• Real-time monitoring of continuous processes (e.g., hot melt extrusion, continuous granulation) to enable closed-loop control.

Operational benefits include reduced cycle times, fewer offline assays, faster process development and more robust process transfer between development and manufacturing sites.

Future trends and potential applications

Several trends are expected to broaden FT-NIR impact in pharmaceutical manufacturing:

• Advanced chemometrics and machine learning – more adaptive, robust models that can handle process drift, instrument variability and complex multivariate signals.
• Digital integration – tighter linkage of FT-NIR data streams into manufacturing execution systems (MES) and distributed control systems (DCS) to enable automated control loops and enhanced data integrity.
• Networked sensor arrays – multiple spectrometers and probes deployed across a process line to provide spatially resolved monitoring and enhanced process understanding.
• Regulatory evolution – wider acceptance of PAT-enabled real-time release testing and model-based control strategies as regulators gain experience with continuous manufacturing and in-line analytics.
• Miniaturization and cost reductions – enabling broader at-line deployment in decentralized production and flexible manufacturing facilities.

Conclusion

FT-NIR spectroscopy, implemented with purpose-built instrumentation, unified software and appropriate sampling strategies, is a mature and practical PAT tool for enabling Quality by Design in pharmaceutical workflows. It provides rapid, non-destructive measurements suitable for development, transfer and production monitoring. Successful deployment requires attention to sampling, chemometric model lifecycle management and integration with process control systems, but when executed well FT-NIR accelerates development, enhances process understanding and supports more consistent product quality.